Latest From Biotech Now

Whole Genome Sequencing and Myriad Supreme Court Case: Nothing to See Here

Supreme Court - Phil Roeder

Bio IT World just published an article stating that the Myriad Supreme Court case will have little to no effect on whole genome sequencing. “As WGS involves determining the sequence of an individual’s entire genome, there is concern in many quarters that WGS could violate essentially every patent covering an isolated human DNA sequence—of which there are thousands. Indeed, this concern has been raised by scholars, policy analysts and lawyers, including before the Federal Circuit Read More >

Patently BIOtech  |  1 Comment  |  Email This Post
Tags: , , , , ,

Public Health at Risk: Don’t Cut Programs that Work

cliff

In order to avoid the “fiscal cliff,” the Congress must compromise and protect our economic future by cutting costs and raising revenue, without compromising our nation’s support for critical government programs. Programs vital to the health of our nation – quite literally – should not suffer dramatic cuts. Making cuts to these programs could actually cost our nation more in the long run. The unintended consequences could impact our economic health, as well as our Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

The Future of Biodefense: Will Public-Private Partnerships Continue?

commercial-jenn

Ten years ago, in the wake of the 2001 anthrax attacks, the U.S. government set out on a bold path to improve the country’s preparedness for bioterrorism by developing and stockpiling new drugs and vaccines to protect Americans from health emergencies.  Individuals from both political parties – many who had experienced bioterror first hand – worked together to harness the power of innovative science and tackle this national security threat. The ten year initiative was Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

New Drug Disposal Law Doesn’t Make Sense

rxpills-btn

Product stewardship is a broad term applied across many industries, encompassing environmental, health, and safety concerns. Companies in each sector of the biotech industry (healthcare, agricultural, and industrial and environmental) have championed stewardship programs for many years – not just because it makes good business sense, but because they believe it is the right thing to do. Within the healthcare space, the impact of pharmaceuticals in the environment has become an issue of emerging debate. Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: ,

Inter Partes Review – a Useful Tool for Overcoming Freedom-to-Operate Obstacles

Basic CMYK

By Eric K. Steffe, Eldora L. Ellison, Ph.D., Todd Spalding, and Deborah A. Sterling, Ph.D. For companies facing freedom-to-operate obstacles, the AIA provides a number of tools for dealing with troublesome patents.  While proceeding at risk in the face of such patents sometimes make sense, inter partes review (IPR) provides a viable option for challenging them and should be considered as a valuable addition to one’s freedom-to-operate toolbox. Inter partes reexamination (IPX), which (bio)pharma used Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , ,